LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

Phase 1

Phase 2

EG-70LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Sponsor:

enGene, Inc.

Code:

NCT04752722

Conditions

Superficial Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EG-70 (phase 1)

EG-70 (phase 2)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-03. This information was provided to ClinicalTrials.gov by enGene, Inc. on 2026-01-26.